Literature DB >> 11827647

Leptomeningeal Neoplasms.

Lauren E. Abrey1.   

Abstract

Leptomeningeal metastases are a late, devastating complication of systemic cancer that typically occurs in conjunction with other systemic relapse. The most common neurologic symptoms include headache, altered mentation, and difficult walking. Diagnosis is established by neuroimaging and cerebrospinal fluid analysis. The prognosis is poor with a median survival of 6 to 8 weeks; therefore most treatment interventions are palliative. Radiotherapy should be given to sites of bulky or symptomatic tumor. Intrathecal chemotherapy is most effective in patients with lymphoma, leukemia, and breast cancer. Systemic chemotherapy may be more effective in treating bulky leptomeningeal tumor. Ventriculoperitoneal shunting can be extremely useful in patients with obstructive hydrocephalus or increased intracranial pressure.

Entities:  

Year:  2002        PMID: 11827647     DOI: 10.1007/s11940-002-0023-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  29 in total

1.  Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis.

Authors:  M H Friedberg; M J Glantz; M S Klempner; B F Cole; G Perides
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

2.  Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors.

Authors:  A Gajjar; M Fouladi; A W Walter; S J Thompson; D A Reardon; T E Merchant; J J Jenkins; A Liu; J M Boyett; L E Kun; R L Heideman
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

3.  Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.

Authors:  G Stockhammer; W Poewe; S Burgstaller; F Deisenhammer; A Muigg; S Kiechl; E Schmutzhard; H Maier; S Felber; P Schumacher; E Gunsilius; G Gastl
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

4.  Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases.

Authors:  M C Chamberlain; P A Kormanik
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

5.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

6.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.

Authors:  R N Hitchins; D R Bell; R L Woods; J A Levi
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

7.  Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy.

Authors:  T Siegal; A Lossos; M R Pfeffer
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

Review 8.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

9.  Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients.

Authors:  H B Coakham; J T Kemshead
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

10.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

View more
  1 in total

1.  Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan.

Authors:  C L Davies; R Chinn; M Nelson; M Rasanesan; B Gazzard; T Powles; M Bower; J Stebbing
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-26       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.